119 related articles for article (PubMed ID: 15841388)
21. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
22. RET polymorphisms and haplotypes and risk of differentiated thyroid cancer.
Ho T; Li G; Zhao C; Wei Q; Sturgis EM
Laryngoscope; 2005 Jun; 115(6):1035-41. PubMed ID: 15933516
[TBL] [Abstract][Full Text] [Related]
23. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
[TBL] [Abstract][Full Text] [Related]
24. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function.
Carter MT; Yome JL; Marcil MN; Martin CA; Vanhorne JB; Mulligan LM
Cytogenet Cell Genet; 2001; 95(3-4):169-76. PubMed ID: 12063395
[TBL] [Abstract][Full Text] [Related]
25. Allelic loss of DNA locus of the RET proto-oncogene in small cell lung cancer.
Futami H; Egawa Si; Takasaki K; Tsukada T; Shiraishi M; Yamaguchi K
Cancer Lett; 2003 May; 195(1):59-65. PubMed ID: 12767512
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of polymerase chain reaction-restriction fragment length polymorphism for RET rs2435357 genotyping as Hirschsprung risk.
Gunadi ; Dwihantoro A; Iskandar K; Makhmudi A; Rochadi
J Surg Res; 2016 Jun; 203(1):91-4. PubMed ID: 27338539
[TBL] [Abstract][Full Text] [Related]
27. 5'-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytomas.
Le Hir H; Charlet-Berguerand N; de Franciscis V; Thermes C
Oncology; 2002; 63(1):84-91. PubMed ID: 12187076
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of disease-related genes: focus on endocrine neoplasias.
Aguiar RC; Dahia PL
Front Horm Res; 2001; 28():20-49. PubMed ID: 11443852
[No Abstract] [Full Text] [Related]
29. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.
Griseri P; Garrone O; Lo Sardo A; Monteverde M; Rusmini M; Tonissi F; Merlano M; Bruzzi P; Lo Nigro C; Ceccherini I
Oncotarget; 2016 May; 7(18):26465-79. PubMed ID: 27034161
[TBL] [Abstract][Full Text] [Related]
30. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.
McKenna NJ; Kieback DG; Carney DN; Fanning M; McLinden J; Headon DR
Br J Cancer; 1995 Mar; 71(3):451-5. PubMed ID: 7880723
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer.
Ghazi Jumaa M
Arch Razi Inst; 2022 Feb; 77(1):205-211. PubMed ID: 35891756
[TBL] [Abstract][Full Text] [Related]
32. Prohibitin expression deregulation in gastric cancer is associated with the 3' untranslated region 1630 C>T polymorphism and copy number variation.
Leal MF; Cirilo PD; Mazzotti TK; Calcagno DQ; Wisnieski F; Demachki S; Martinez MC; Assumpção PP; Chammas R; Burbano RR; Smith MC
PLoS One; 2014; 9(5):e98583. PubMed ID: 24879411
[TBL] [Abstract][Full Text] [Related]
33. Analysis of clinically relevant single-nucleotide polymorphisms by use of microelectronic array technology.
Santacroce R; Ratti A; Caroli F; Foglieni B; Ferraris A; Cremonesi L; Margaglione M; Seri M; Ravazzolo R; Restagno G; Dallapiccola B; Rappaport E; Pollak ES; Surrey S; Ferrari M; Fortina P
Clin Chem; 2002 Dec; 48(12):2124-30. PubMed ID: 12446467
[TBL] [Abstract][Full Text] [Related]
34. Absence of the RET+3:T allele in the MTC patients.
Borun P; Jerzy S; Ziemnicka K; Kubaszewski L; Lipinski D; Plawski A
Hered Cancer Clin Pract; 2012 Oct; 10(1):14. PubMed ID: 23088776
[TBL] [Abstract][Full Text] [Related]
35. Reduction to homozygosity at the SIS/PDGF-2 locus in human mesenchymal tumors.
Shin DM; Ince C; Shtalrid M; Lee JS; Ro JS; Donner L; Ferrell RE; Hong WK; Wildrick D; Blick M
Biochem Biophys Res Commun; 1988 Sep; 155(2):692-9. PubMed ID: 2901834
[TBL] [Abstract][Full Text] [Related]
36. A Taqi RFLP of the human TGF alpha gene is significantly associated with cutaneous malignant melanoma.
Hayward N; Nancarrow D; Ellem K; Parsons P; Kidson C
Int J Cancer; 1988 Oct; 42(4):558-61. PubMed ID: 2902017
[TBL] [Abstract][Full Text] [Related]
37. Expression of the protein product of the PCPH proto-oncogene in human tumor cell lines.
Rouzaut A; Recio JA; Notario V
Radiat Res; 2001 Jan; 155(1 Pt 2):181-187. PubMed ID: 11121232
[TBL] [Abstract][Full Text] [Related]
38. RET-fusions: a novel paradigm in colorectal cancer.
Santos C; Sanz-Pamplona R; Salazar R
Ann Oncol; 2018 Jun; 29(6):1340-1343. PubMed ID: 29648570
[No Abstract] [Full Text] [Related]
39. 65 YEARS OF THE DOUBLE HELIX: Endocrine tumour syndromes in children and adolescents.
Goudie C; Hannah-Shmouni F; Kavak M; Stratakis CA; Foulkes WD
Endocr Relat Cancer; 2018 Aug; 25(8):T221-T244. PubMed ID: 29986924
[TBL] [Abstract][Full Text] [Related]
40. Hereditary endocrine neoplasias: fundamental insights and the practice of clinical cancer genetics.
Dahia PL; Eng C
Front Horm Res; 2001; 28():8-19. PubMed ID: 11443854
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
